LIFEVANTAGE CORP Contract Liability (Deferred Revenue)
LIFEVANTAGE CORP (LFVN) had Contract Liability (Deferred Revenue) of $1.15 million as of 2026-06-30, per its 10-K filed 2026-08-27.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-27
- 2026-06-30: Contract with Customer, Liability, Current $1.15M.
- 2026-03-31: Contract with Customer, Liability, Current $1.00M.
- 2025-12-31: Contract with Customer, Liability, Current $700.00K.
- 2025-09-30: Contract with Customer, Liability, Current $700.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $1.15M 10-K · filed 2026-08-27 |
| 2026-03-31 | $1.00M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $700.00K 10-Q · filed 2026-02-04 |
| 2025-09-30 | $700.00K 10-Q · filed 2025-11-04 |
| 2025-06-30 | $711.00K 10-K · filed 2026-08-27 |
| 2025-03-31 | $1.30M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $1.40M 10-Q · filed 2025-02-05 |
| 2024-09-30 | $1.10M 10-Q · filed 2024-10-29 |
| 2024-06-30 | $860.00K 10-K · filed 2025-09-04 |
| 2024-03-31 | $700.00K 10-Q · filed 2024-05-02 |
| 2023-12-31 | $900.00K 10-Q · filed 2024-01-30 |
| 2023-09-30 | $1.00M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $834.00K 10-K · filed 2024-08-28 |
| 2022-06-30 | $78.00K 10-K · filed 2023-08-28 |
| 2021-06-30 | $319.00K 10-K · filed 2022-08-23 |
| 2020-06-30 | $792.00K 10-K · filed 2021-08-19 |
| 2019-06-30 | $998.00K 10-K · filed 2020-08-18 |
| 2018-06-30 | $1.11M 10-K · filed 2019-08-14 |
| 2017-06-30 | $1.74M 10-K · filed 2018-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |